Maung Myo Htut, M.D.

800-826-4673
Maung Htut
Hematologist
4.9 (157 RATINGS)
Clinical Expertise
Hematology-Oncology
Hematology & Hematopoietic Cell Transplantation
Multiple Myeloma
Research Area
Multiple Myeloma
Appointments
Associate Professor, Division Of Myeloma, Department Of Hematology And Hematopietic Cell Transplantation
Clinical Teams
Myeloma And Multiple Myeloma
Hematology & Hematopoietic Cell Transplantation
"There’s a real need for additional therapies for myeloma." — Maung Myo Htut, M.D.
Dr. Htut is determined to find more effective treatments for multiple myeloma, a rare blood cancer that strikes about 30,000 Americans each year. He believes the body's own immune system may hold the key. He's especially excited about the potential of CAR T cells – immune cells taken from the patient, re-engineered to destroy cancer, then re-introduced.
 
“It’s like we’re taking infantry soldiers and training them to be Navy SEALs whose only job is to find and kill these cancer cells,” he says.
 
A native of Myanmar, Dr. Htut received his medical degree at Yangon's Institute of Medicine. After interning at Yangon General Hospital he completed his residency at Harbor Hospital, Baltimore, as well as fellowships at University of Colorado and here at City of Hope.
 
Dr. Htut is conducting multiple clinical trials examining immunotherapy options for multiple myeloma. Rounding out a decade at City of Hope, Dr. Htut says it is the “best place to take care of patients as well as doing research.”
Location
Education & Experience
Board Certifications

  • California State Medical License (active)

  • Colorado State Medical License (active)

  • 1997, General Medical Council, UK

  • ECFMG certified

  • Diplomate, American Board of Internal Medicine

Degrees

  • 1998, Education Commission for Foreign Medical Graduates

  • 1995, M.B., B.S., Institute of Medicine (1), Yangon, Myanmar

Fellowship

  • 2009 - 2010, HCT Fellow, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, CA

  • 2007 -2009, Oncology Fellow, University of Colorado, Denver, CO

Residency

  • 1999 -2002, Resident, Internal Medicine, Harbor Hospital, Baltimore, MD

Internship

  • 1995 -1996, Intern, Internal Medicine, Yangon General Hospital, Yangon, Myanmar

Professional Experience

  • 2019 - present, Associate Professor, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2010 - 2019, Assistant Clinical Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2009 - 2010, Hematopoietic Cell Transplantation Fellow, City of Hope, Duarte, CA

  • 2007 - 2009, Oncology Fellow, University of Colorado, Denver, CO

  • 2002 - 2007, Hospitalist , High desert Medical Group, Lancaster, CA

  • 1999 - 2002, Residency Program (Internal Medicine) Harbor Hospital, Baltimore, MD

Publications
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049. PMID: 31590151
  • Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23. PMID: 29061640
  • Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now? Htut M. Curr Hematol Malig Rep. 2019 Feb;14(1):1-10. doi: 10.1007/s11899-019-0492-z. PMID: 30666505
  • NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154-1165. doi: 10.6004/jnccn.2019.0049. PMID: 31590151
  • Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, Wong CW, Chang WC, Thomas SH, Sanchez JF, Yang L, Brown CE, Pichiorri F, Htut M, Krishnan AY, Forman SJ. Clin Cancer Res. 2018 Jan 1;24(1):106-119. doi: 10.1158/1078-0432.CCR-17-0344. Epub 2017 Oct 23. PMID: 29061640
  • Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Transplant. 2017 Oct 24. pii: S1083-8791(17)30793-0. DOI: 10.1016/j.bbmt.2017.10.024. [Epub ahead of print]. 
  • Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL.A phase !dose-escalation study on filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15;122(21):3327-333.5. DOI: 10.1002/cncr.30174. PMID: 27433944. 
  • Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, HtutM, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-hodgkin lymphoma. Haematologica. 2015 Mar; 100(3):357-62. DOI: 10.3324/haematol.2014.117473 PMID:25596263. 
  • Twice-weekly Oral Ixazomib Citrate (MLN9708), an Investigational Proteasome Inhibitor, in Combination with Lenalidomide (Len) and Dexamethasone (Dex) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data -ASH poster 2013. 
  • Deauna-Limayo D, Rajabi B, Qiu W, Htut, M, Swetenham J. Kaposi's Sacroma After Non-Myeloablative Hematopoietic Stem Cell Transplant: Response to Withdraw! of Immunosuppressant Therapy Correlated with Whole Blood Human Herpes Virus-8 RT-PCR levels. Leuk Lymphoma. 2013 Jan 24. [Epub ahead of print]. 
  • Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ. Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study. Br J Haematol. 2013 Jan;l60(2):199-206. DOI: 10.1111/bjh.12123. Epub 2112 Nov 15. 
  • Krishnan AY, Mei M, Sun CL, Thomas SH, Teh JB, Kang T, Htut M, Somlo G, Sahebi F, Forman SJ, Bhatia S. Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant, 2012 Oct 13. Pii: Sl083-8791(12)00418-l doi: 10.1016/j.bbmt.2012.09.023 Epub 2012 Oct 13. 
  • Information listed here is obtained from Pubmed, a public database; City of Hope is not responsible for its accuracy.
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Provider listen carefully to you
5.0
Show respect for what you say
4.9
Rate provider 0-10
4.9
Recommend this provider office
4.9
Know important info medical history
4.9
Spend enough time with you
4.8
Provider explain in way you understand
Reviews
02/06/23
I feel welcome and acknowledged here at the City of Hope, from the time I get my lab work [...] to the time I'm with Dr. Htut. Caring, friendly and patient-centered. - Verified patient
02/06/23
Dr. Htut has known me and my wife for over 10 years now. He is very knowledgeable about new treatments and therapies out there that are available to me. - Verified patient
11/08/22
Dr. Htut was very comprehensive. - Verified patient
10/29/22
Extremely pleased with doctor in the professional care as well as making sure we understand each and every step in our healing process. - Verified patient
09/15/22
I am very fortunate to have Dr. Htut as my doctor. He is so nice and easy to talk to. I feel he gives me hope of remission in this clinical trial I am currently in. - Verified patient